CLDX / Celldex: Long List Of Failures, High Valuation, But Good Data Recently

HAMPTON, N.J., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fires more_horizontal

Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.65 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.5 more_horizontal

HAMPTON, N.J., June 02, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a firesi more_horizontal

Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to more_horizontal

Celldex (CLDX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the s more_horizontal

HAMPTON, N.J., March 29, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fires more_horizontal

Celldex has failed too many times to inspire confidence. The company's current valuation is also quite high. more_horizontal

Celldex (CLDX) delivered earnings and revenue surprises of 0% and 62.80%, respectively, for the quarter ended September 2022. Do the numbers hold clue more_horizontal